Natamycin Cyclodextrin Supramolecular Complex Loaded Dissolvable Lenses for the Effective Management of Fungal Keratitis

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Mabel Mascarenhas, Pinal Chaudhari, Lakshmi Sruthi Mallela, Sanhita Roy, Sumit Birangal, Vivek Ghate, Ananthamurthy Koteshwara, Jesil Aranjani, Arun K. Kodoth, Shaila A. Lewis
{"title":"Natamycin Cyclodextrin Supramolecular Complex Loaded Dissolvable Lenses for the Effective Management of Fungal Keratitis","authors":"Mabel Mascarenhas,&nbsp;Pinal Chaudhari,&nbsp;Lakshmi Sruthi Mallela,&nbsp;Sanhita Roy,&nbsp;Sumit Birangal,&nbsp;Vivek Ghate,&nbsp;Ananthamurthy Koteshwara,&nbsp;Jesil Aranjani,&nbsp;Arun K. Kodoth,&nbsp;Shaila A. Lewis","doi":"10.1007/s12247-025-10137-x","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>The only commercially available topical treatment for Fungal Keratitis (FK) that has been approved by the United States Food and Drug Administration (US FDA) is the 5% w/v suspension of Natamycin (Nat). Its very poor water solubility (~ 30–50 mg/L), which limits its absorption and therapeutic efficacy, is the main disadvantage that limits its clinical use. A lengthy dose schedule, low ocular retention, and a &lt; 5% ocular bioavailability are the main disadvantages of topical ocular administration therapy.</p><h3>Methods</h3><p>The present study aimed to increase the aqueous solubility of natamycin and furthermore, increase its retention at the ocular surface by incorporating it into a dissolvable lens. Novel ophthalmic formulations were formulated with Natamycin-Sulfobutylether-β-cyclodextrin (Nat/SBE-β-CD) binary complex and ternary complexes with Polyvinyl alcohol or Poloxamer 407 (Nat/SBE-β-CD/PVA and Nat/SBE-β-CD/P407, respectively). In silico molecular modelling and wet lab experiments were performed to confirm the stability and complex formation. Furthermore, the complexes were incorporated into marketed and dissolvable contact lenses (CLs) and evaluated for in vitro antifungal studies and in vivo drug distribution to investigate their therapeutic efficacy and increased precorneal retention and permeation.</p><h3>Results</h3><p>The binary complex improved the Nat solubility up to ~ 80 fold, whereas the ternary complexes enhanced the drug solubility by ~ 107 fold and ~ 98 fold as compared to the pure drug. Cytocompatibility studies confirmed the safety and non-irritancy of the optimized formulations. The dissolvable CLs demonstrated greater drug loading, higher ex vivo transcorneal permeation, and antifungal efficacy than the soaked marketed CLs, which showed a sustained in vitro drug release. The binary dissolvable CLs showed higher in vivo corneal drug concentrations than the other CLs.</p><h3>Conclusion</h3><p>This study demonstrates the potential of CL-loaded inclusion complexes as alternatives to the currently approved suspension therapy for treating FK.</p><h3>Graphical Abstract</h3><p>Contact lens loaded Inclusion Complexes of Natamycin: A Potential Alternative to Conventional Suspension Therapy for Fungal Keratitis</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 6","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10137-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

The only commercially available topical treatment for Fungal Keratitis (FK) that has been approved by the United States Food and Drug Administration (US FDA) is the 5% w/v suspension of Natamycin (Nat). Its very poor water solubility (~ 30–50 mg/L), which limits its absorption and therapeutic efficacy, is the main disadvantage that limits its clinical use. A lengthy dose schedule, low ocular retention, and a < 5% ocular bioavailability are the main disadvantages of topical ocular administration therapy.

Methods

The present study aimed to increase the aqueous solubility of natamycin and furthermore, increase its retention at the ocular surface by incorporating it into a dissolvable lens. Novel ophthalmic formulations were formulated with Natamycin-Sulfobutylether-β-cyclodextrin (Nat/SBE-β-CD) binary complex and ternary complexes with Polyvinyl alcohol or Poloxamer 407 (Nat/SBE-β-CD/PVA and Nat/SBE-β-CD/P407, respectively). In silico molecular modelling and wet lab experiments were performed to confirm the stability and complex formation. Furthermore, the complexes were incorporated into marketed and dissolvable contact lenses (CLs) and evaluated for in vitro antifungal studies and in vivo drug distribution to investigate their therapeutic efficacy and increased precorneal retention and permeation.

Results

The binary complex improved the Nat solubility up to ~ 80 fold, whereas the ternary complexes enhanced the drug solubility by ~ 107 fold and ~ 98 fold as compared to the pure drug. Cytocompatibility studies confirmed the safety and non-irritancy of the optimized formulations. The dissolvable CLs demonstrated greater drug loading, higher ex vivo transcorneal permeation, and antifungal efficacy than the soaked marketed CLs, which showed a sustained in vitro drug release. The binary dissolvable CLs showed higher in vivo corneal drug concentrations than the other CLs.

Conclusion

This study demonstrates the potential of CL-loaded inclusion complexes as alternatives to the currently approved suspension therapy for treating FK.

Graphical Abstract

Contact lens loaded Inclusion Complexes of Natamycin: A Potential Alternative to Conventional Suspension Therapy for Fungal Keratitis

Abstract Image

纳他霉素环糊精超分子络合物负载可溶晶状体有效治疗真菌性角膜炎
目的:美国食品和药物管理局(FDA)批准的唯一市售的真菌角膜炎(FK)局部治疗方法是5% w/v的纳他霉素(Nat)混悬液。其水溶性极差(~ 30 ~ 50mg /L),限制了其吸收和治疗效果,是限制其临床应用的主要缺点。较长的给药时间、较低的眼潴留和5%的眼生物利用度是眼部局部给药治疗的主要缺点。方法本研究旨在通过将纳他霉素掺入可溶晶状体中,提高其在眼表的溶解度和保留率。以纳他霉素-磺基丁醚-β-环糊精(Nat/SBE-β-CD)二元配合物和与聚乙烯醇或波洛沙姆407 (Nat/SBE-β-CD/PVA和Nat/SBE-β-CD/P407)三元配合物配制新型眼科配方。在硅分子模型和湿实验室实验,以确认稳定性和复杂的形成。此外,该复合物被纳入市售和可溶隐形眼镜(CLs),并进行体外抗真菌研究和体内药物分布评估,以调查其治疗效果和增加角膜前保留和渗透。结果二元配合物的溶解度提高了约80倍,三元配合物的溶解度分别提高了约107倍和98倍。细胞相容性研究证实了优化配方的安全性和无刺激性。与浸渍的市售CLs相比,可溶CLs表现出更大的药物负荷、更高的体外经角膜渗透和抗真菌效果,并表现出持续的体外药物释放。双溶性CLs体内角膜药物浓度高于其他CLs。结论:本研究证明了cl负载包合物作为替代目前批准的悬浮剂治疗FK的潜力。接触镜负载纳他霉素包合物:传统悬浮液治疗真菌性角膜炎的潜在替代方案
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信